David Wild
Reporter
Latest From David Wild
Podcast: Improving Communication – The Relationship Between Biotech And Pharma
Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma.
The Biotech Balancing Act: Long-Term Vision Vs. Inflection Points
Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech.
BioBytes: AI-Related Deals In Q2 2024
Dominated by Xaira Therapeutics' $1bn venture financing, Q2 2024 was also notable for sizeable public offerings by Alumis and Recursion Therapeutics in the US and XtalPi Technology in Hong Kong, as well as a $142m seed round for EvolutionaryScale.
Poland’s Quiet Pivot From Generics To Innovative Treatments
Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.
Gain Therapeutics Navigates Market Fluctuations While Developing Parkinson’s Treatment
Gain Therapeutics aims to offer a disease-modifying treatment for Parkinson’s patients with GCase mutations. The company’s promising data and platform face competition from notable rivals.
A GenAI Copilot For The Regulatory Affairs Team
A GenAI copilot for biopharma regulatory requirements could yield significant returns.